Clinical Trial: A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608757) titled 'A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat' on May 20.

Brief Summary: A phase 2b, randomized, placebo#controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.

Study Start Date: Feb., 2027

Study Type: INTERVENTIONAL

Condition: Subcutaneous Fat

Intervention: DRUG: CBL-514 Injection

Provided as a ready for use injectable CBL-514 solution

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Caliway Biopharmaceuticals Co., Ltd.

Published by HT Digital Content...